indication

Schizophreniform Disorders

Competitive landscape projected to Mindfulness psychoeducation Programme’s launch window

as of 2026-07-01
Competitive set
5
5 approved · 0 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
44 events
2020
2024
2028
2032
2036
2040
today
Mindfulness psychoeducation Programme launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Risperidone
US-approved 1993 · RISPERDAL
—2 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugCompleted
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
Phase 32 trials
OwnerEli Lilly and Company
Protection2041
drugCompleted
Paliperidone
US-approved 2006 · Erzofri extended-release
Phase 11 trial
OwnerJohnson & Johnson
Protection2041
drugCompleted
Quetiapine
US-approved 1997 · SEROQUEL XR
—1 trial
OwnerAstraZeneca
Protection—
drugCompleted
Aripiprazole
US-approved 2002 · ABILIFY
Phase 41 trial
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041

Market size

prevalence as a range, not a number